Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
USPSTF Guidelines for HT in Postmenopausal Women
JAMA; 2017 Dec 12; US Preventive Services Task Force
The US Preventive Services Task Force (USPSTF) has issued a recommendation statement for hormone therapy for the primary prevention of chronic conditions in postmenopausal women. The guideline updates the 2012 USPSTF recommendation and determined after a review of the evidence (18 clinical trials) that although the use of hormone therapy to prevent chronic conditions in postmenopausal women is associated with some benefits, there is also a substantial increase in risk of harms. The updated recommendation statement reads:
- The USPSTF recommends against the use of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal women. (D recommendation)
- The USPSTF recommends against the use of estrogen alone for the primary prevention of chronic conditions in postmenopausal women who have had a hysterectomy. (D recommendation)
US Preventive Services Task Force. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women. US Preventive Services Task Force recommendation statement. JAMA. 2017;318(22):2224–2233. doi:10.1001/jama.2017.18261.
This Week's Must Reads
Must Reads in Clinical Guidelines
ACOG: Chronic Hypertension in Pregnancy, Obstet Gynecol; ePub 2019 Jan; Vidaeff, et al
ACOG Guidelines: Pregestational Diabetes Mellitus, Obstet Gynecol; ePub 2018 Dec; ACOG, et al
Management of Early Pregnancy Loss, Obstet Gynecol; ePub 2018 Nov; ACOG
Prophylactic Antibiotic Use in Labor & Delivery, Obstet Gynecol; 2018 Sep; Coleman, et al
USPSTF on Screening for Cervical Cancer, JAMA; 2018 Aug 21; US Preventive Services Task Force
